Eurofins Reinforces Its Market Leadership in Environment Testing with the Acquisition of Nab Labs in Finland
2017年6月1日 - 3:30PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global leader in food and
environment testing, announces that it has acquired Nab Labs Group
Oy (“Nab Labs”), one of the largest independent environment testing
laboratories in Finland.
Nab Labs provides a comprehensive range of environmental
research and testing services nationwide, with a strong competence
in industrial process analytics and forestry sectors. Founded in
1968, the company employs over 100 staff and generates annual
revenues in excess of EUR 9m.
Nab Labs’ operational and geographical footprint is
complementary to Eurofins’ network in Finland. This acquisition
therefore firmly consolidates the Group’s market leadership in
environment testing, established following the recent acquisitions
of Ramboll Labs, which hold a strong position in southern Finland,
and Ahma, a leading provider in the north of the country.
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of Nab Labs is another illustration of Eurofins’
commitment to consolidating the Group’s leading footprint in the
markets where it operates. Together with the recently-acquired Ahma
and Ramboll networks of laboratories in the country, we look
forward to supporting these laboratories’ respective operations and
further developing their capabilities to continue providing
customers in Finland with the highest level of analytical
service”.
For more information about Eurofins, please visit
www.eurofins.com or contact:
Investor RelationsEurofins Scientific Group+32 2 766
1620ir@eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170531006581/en/
Investor RelationsEurofins Scientific Group+32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024